Abstract P6-08-04: Preclinical efficacy of dasatinib in combination with PARP inhibitor plus standard cytotoxic agent in triple-negative breast cancer xenograft model

2017 ◽  
Author(s):  
Y Sun ◽  
X Lin ◽  
JH Carlson ◽  
P De ◽  
N Dey ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Parp Inhibitor ◽  
Xenograft Model ◽  
Cytotoxic Agent ◽  
Breast Cancer Xenograft ◽  
Preclinical Efficacy

scholarly journals Synergistic Interaction Betweem Olaparib, a Parp Inhibitor, and Cytotoxic Agent in Triple Negative Breast Cancer

2013 ◽  
Vol 24 ◽  
pp. ix59 ◽  
Author(s):  
J. Hashimoto ◽  
Y. Kitamura ◽  
Y. Takashima ◽  
Y. Kodera ◽  
S. Shimma ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Parp Inhibitor ◽  
Synergistic Interaction ◽  
Cytotoxic Agent

scholarly journals MEK Inhibitor Selumetinib (AZD6244; ARRY-142886) Prevents Lung Metastasis in a Triple-Negative Breast Cancer Xenograft Model

2015 ◽  
Vol 14 (12) ◽  
pp. 2773-2781 ◽  
Author(s):  
Chandra Bartholomeusz ◽  
Xuemei Xie ◽  
Mary Kathryn Pitner ◽  
Kimie Kondo ◽  
Ali Dadbin ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lung Metastasis ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Xenograft Model ◽  
Mek Inhibitor ◽  
Breast Cancer Xenograft
Sign in / Sign up

Export Citation Format

Share Document